- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Witwatersrand University (Wits) in Johannesburg, South Africa, began screening for a Phase 3 trial of COVID-19 Novavax vaccine in August 2020.
A US$15 million grant towards the trial was awarded to Novavax by the Bill & Melinda Gates Foundation. The trial involves 2,665 healthy adults and nearly 240 medically stable, HIV-positive adults.
“’The major motivation for COVID-19 vaccines being evaluated at an early stage in South Africa is to generate evidence in the African context on how well these vaccines work in settings such as our own’, says principle investigator of the Novavax clinical trial Shabir Madhi, Wits Professor of Vaccinology.”
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
